TAK-881
- Generic Name
- TAK-881
Expanded Access to TAK-881 for Children and Teenagers With Primary Immunodeficiency Diseases in the USA
- Conditions
- Primary Immunodeficiency Diseases (PIDD)
- First Posted Date
- 2025-05-02
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Takeda
- Registration Number
- NCT06955793
A Study of TAK-881 With and Without Ramp-Up Dosing in Healthy Adults
Phase 1
Recruiting
- Conditions
- Healthy Volunteers
- Interventions
- Device: SC Investigational Needle Sets
- First Posted Date
- 2025-04-20
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Takeda
- Target Recruit Count
- 64
- Registration Number
- NCT06935266
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
A Study of TAK-881 and HyQvia in Healthy Adults
Phase 1
Recruiting
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2025-03-26
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Takeda
- Target Recruit Count
- 30
- Registration Number
- NCT06895967
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Phase 3
Not yet recruiting
- Conditions
- Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
- Interventions
- First Posted Date
- 2024-12-24
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- Takeda
- Target Recruit Count
- 59
- Registration Number
- NCT06747351
A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases
Phase 3
Recruiting
- Conditions
- Primary Immunodeficiency Diseases (PID)
- Interventions
- Device: SC Investigational Needle Sets
- First Posted Date
- 2023-10-11
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Takeda
- Target Recruit Count
- 39
- Registration Number
- NCT06076642
- Locations
- 🇺🇸
Montefiore Medical Center, Bronx, New York, United States
🇺🇸Duke Asthma, Allergy and Airway Center, Durham, North Carolina, United States
🇺🇸Allergy Partners of North Texas, Dallas, Texas, United States
A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases
Phase 2
Active, not recruiting
- Conditions
- Primary Immunodeficiency Diseases (PID)
- Interventions
- First Posted Date
- 2023-03-06
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Takeda
- Target Recruit Count
- 65
- Registration Number
- NCT05755035
- Locations
- 🇺🇸
University of California Irvine Medical Center, Irvine, California, United States
🇺🇸Allergy and Asthma Clinical Research, Walnut Creek, California, United States
🇺🇸National Jewish Medical And Research Center, Denver, Colorado, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath